PHAXIAM Reveals Meeting Prep Documents for June 2024 General Session

PHAXIAM Therapeutics Announces General Meeting Details

PHAXIAM Therapeutics has released important preparatory documents for its upcoming Combined General Meeting, scheduled for 28 June 2024. This announcement includes vital information for shareholders looking to participate in the annual gathering.

The meeting will be held at the company's registered office located at 60 avenue Rockefeller, Lyon, France, commencing at 9:30 a.m. CET. Attendees will engage in various discussions crucial to the company's future.

Accessing Meeting Documents

Shareholders can access the preparatory documents, including the agenda and draft resolutions, through the PHAXIAM website under the 'Investors / General Meeting / 2024' section. These documents are made available in adherence to legal and regulatory requirements and provide crucial insights into the meeting topics.

It is recommended that shareholders regularly check this section for updates that might detail the final arrangements of the meeting.

About PHAXIAM Therapeutics

PHAXIAM Therapeutics is a notable player in the field of infectious disease treatment. The company focuses on developing innovative therapies targeting severe and resistant bacterial infections using phages—viruses that naturally kill bacteria. Their current portfolio includes treatments aimed at combating Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.

With a presence on the Euronext regulated market in Paris, PHAXIAM is listed under the ticker PHXM and participates in various health-related indexes. The firm's innovative approach continues to garner attention within the biopharmaceutical sector.

Clinical and Regulatory Strategies

PHAXIAM consistently works on advancing its clinical programs and regulatory strategies to improve patient outcomes. The company is committed to addressing the growing issue of antibiotic resistance through its cutting-edge research and development tactics.

By leveraging phage therapy, PHAXIAM aims to provide effective treatments for infections that are increasingly becoming resistant to traditional antibiotics.

Importance of the Combined General Meeting

The Combined General Meeting is a vital event for PHAXIAM and its shareholders. It provides a platform to review the company's progress, deliberate on future strategies, and make significant decisions that will shape its operational and financial direction.

Shareholders' active participation in this meeting is crucial, as it ensures that their voices are heard and considered in the company's decision-making process.

Forward-looking Statements

This announcement contains forward-looking statements regarding PHAXIAM's future plans and expected performance. These statements are based on current assumptions and predictions, which may be subject to change. Shareholders and potential investors are advised to consider these factors carefully.

For a detailed overview of the risks and uncertainties, refer to the risk factors section in PHAXIAM's regulatory filings with the French Autorité des Marchés Financiers (AMF).

PHAXIAM's Market Impact

PHAXIAM's pioneering work in developing phage-based therapies has the potential to transform the field of infectious diseases. By addressing resistant bacterial infections, PHAXIAM aims to significantly impact public health outcomes and provide new hope for patients suffering from hard-to-treat infections.

The company's efforts are aligned with global health priorities to combat antibiotic resistance and improve treatment options for chronic bacterial infections.